Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Grows By 53.4%

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 341,700 shares, an increase of 53.4% from the August 31st total of 222,800 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 306,300 shares, the days-to-cover ratio is currently 1.1 days.

Iterum Therapeutics Stock Performance

NASDAQ:ITRM opened at $1.06 on Friday. Iterum Therapeutics has a one year low of $0.62 and a one year high of $2.50. The business’s 50-day simple moving average is $1.15 and its 200 day simple moving average is $1.34. The stock has a market cap of $17.47 million, a price-to-earnings ratio of -0.40 and a beta of 2.26.

Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.22. On average, equities research analysts predict that Iterum Therapeutics will post -1.19 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Iterum Therapeutics in a research note on Tuesday, September 10th.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.